 |  |  | Current Jobs | Not displayed, CONTACT the Zenopa Account Manager Nikki on 01494 818032 or nikki@zenopa.com for CURRENT and future vacancies.
|  |  | Previous Jobs
Hospital Specialist Location: West and East Yorkshir
Healthcare Partnership Manager Location: North East
Sales Analyst Location: Slough, Berkshire
Hospital Specialist x 2 Location: South Coast
Hospital Specialist Location: North West
Healthcare Partnership Manager Location: South East
Healthcare Partnership Manager Location: North TBC
Hospital Specialist Location: East Midlands / Trent
Hospital Specialist Location: Scotland
Hospital Specialist Location: South Wales
Hospital Specialist Location: Oxford, North and West
Hospital Specialist Location: Central and NW London,
Hospital Specialist Location: North East
Hospital Specialist Location: Thames Valley
Hospital Specialist Location: Northern Ireland
|  |
|  | UCB Pharmaceuticals Jobs Profile | UCB is a biopharma leader dedicated to the research, development and commercialisation of medicines to treat patients suffering from severe diseases. With a unique combination of expertise in biology and chemistry, UCB is a global organisation focusing on severe diseases in two therapeutic areas - CNS and Immunology.UCB has a dynamic sales focus in which Hospital Specialists thrive in an environment of continuous improvement, empowerment and entrepreneurship. Working with autonomy, they are driven by results and have the ability to put patients at the centre of all they do. With a new launch in Rheumatology on the horizon, UCB is currently looking for exceptional individuals to form a sales team who will bring their innovative product to market. This team will have a significant impact on shaping the future of UCB and so we are looking for enthusiastic and talented professionals who thrive on challenge and change, who want to make a difference and deliver results. UCB is an R&D driven company, investing over 21% of sales in R&D every year. UCB has a rich and productive pipeline of large and small molecules with eleven novel compounds (including four large, antibody-based molecules and seven small, chemically-derived molecules) that are in clinical development, addressing 13 different types of severe disease, from multiple sclerosis and Parkinson's disease to rheumatoid arthritis. Out of the eleven novel compounds, many are in late stage development (Phase III or filing). UCB believes that this pipeline possesses immense potential for future growth as well as improving the quality of life for patients. |

|  |
|
|  | Nikki UCB Pharmaceuticals Account Manager 01494 818032 (Mon to Fri 0830 to 1800 hours) nikki@zenopa.com
|  |
| Company Reports | 14/10/2008 Accounts
You need to be logged in to view these reports, please login first then return to this page. |  | |